Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-ended, Adaptative, Open Label Dose Escalation and Expansion Clinical Trial to Evaluate the Efficacy and Safety of Unilateral Intracochlear Injection of SENS-501 Using an Injection System in Children With Severe to Profound Hearing Loss Due to Otoferlin Gene Mutations

NCT06370351 is registered in ClinicalTrials.gov with Sensorion as lead sponsor.

NCT NCT06370351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06370351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-ended, Adaptative, Open Label Dose Escalation and Expansion Clinical Trial to Evaluate the Efficacy and Safety of Unilateral Intracochlear Injection of SENS-501 Using an Injection System in Children With Severe to Profound Hearing Loss Due to Otoferlin Gene Mutations
Lead sponsor
Sensorion
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 21, 2024
Completion date
July 31, 2031
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

congenital deafness, deafness, dfnb9, ear diseases, hearing disorders, hearing loss, sensorineural, otof gene mutation, otorhinolaryngologic diseases